Liraglutide and exercise combination aims to boost muscle microvascular perfusion, insulin action in metabolic syndrome

Metabolic Syndrome is a cluster of conditions including central obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels, significantly increasing risk for Type 2 Diabetes and cardiovascular disease. A key feature is insulin resistance, where cells fail to respond adequately to insulin, leading to elevated blood glucose. Impaired muscle microvascular perfusion and endothelial dysfunction are also implicated, hindering nutrient and oxygen delivery to muscle and contributing to insulin resistance. Current interventions often involve lifestyle changes (diet, exercise) and pharmacotherapy, but comprehensive strategies targeting both vascular health and insulin sensitivity are needed. GLP-1 receptor agonists like liraglutide are known for their glucose-lowering and cardiovascular benefits, while exercise is a cornerstone for improving metabolic health. This study explores their individual and combined potential to address these gaps.

This is a Phase 4 randomized controlled trial (NCT03883412) enrolling 60 estimated adults with Metabolic Syndrome and Type 2 Diabetes. Subjects are randomized into four groups: control, exercise training, liraglutide treatment, or exercise + liraglutide. The intervention duration is 24 weeks, with assessments at baseline and post-intervention. Primary objectives include examining changes in cardiac and skeletal muscle microvascular blood volume, vascular function of conduit vessels, and insulin's metabolic action. Microvascular perfusion and insulin sensitivity are key endpoints.

This record describes the design and objectives of an ongoing or planned Phase 4 clinical trial (NCT03883412) and does not present completed results. The study aims to recruit 60 participants with Metabolic Syndrome and Type 2 Diabetes to evaluate the effects of liraglutide, exercise, or their combination over 24 weeks. Specific findings regarding changes in muscle microvascular blood volume, vascular function, or insulin's metabolic action are not yet available. The trial completion is estimated for December 2025.